公开(公告)号：US20220305026A1

公开(公告)日：2022-09-29

申请号：US17829633

申请日：2022-06-01

申请人： Jiangnan University

发明人： Yongquan CHEN ,  Rong WANG ,  Shenglong ZHU ,  Xiaoying WANG ,  Yuanyuan MI ,  Sheng WU ,  Jian SUN

IPC分类号： A61K31/555 ,  A61K31/4166 ,  A61K31/58 ,  A61K31/502 ,  A61P35/00

摘要： The present disclosure discloses use of polaprezinc (Pola) in preparing a drug for treating castration-resistant prostate cancer (CRPC) and belongs to the technical field of biological medicine. The present disclosure provides a new strategy for preparing the drug for treating the CRPC by combining the Pola with an androgen receptor antagonist for the first time and conducts a multi-angle and multi-level verification research. A drug composition combining the polaprezinc and the androgen receptor antagonist can be used for treating castration-resistant prostate cancer, remarkably improves an effect of enzalutamide in inhibiting the castration-resistant prostate cancer, realizes new use of the old drug, can greatly shorten time from drug discovery to clinical transformation, and has important clinical treatment significance.

公开(公告)号：US20180237789A1

公开(公告)日：2018-08-23

申请号：US15954805

申请日：2018-04-17

申请人： JIANGNAN UNIVERSITY

发明人： Haiqin CHEN ,  Wei CHEN ,  Yongquan CHEN ,  Guangfei HAO ,  Xin TANG ,  Zhennan GU ,  Jianxin ZHAO ,  Hao ZHANG

IPC分类号： C12N15/80 ,  C12N9/10

CPC分类号： C12N15/80 ,  C12N9/1077 ,  C12P7/6472 ,  C12Y204/0201

摘要： It relates to a Mortierella alpine ATCC32222 uracil auxotroph strain and a construction method thereof. In the present invention, Mortierella alpine ATCC32222 is used as a material and undergoes gene knockout through an Agrobacterium tumefaciens mediated genetic manipulation technology, to obtain the Mortierella alpine uracil auxotroph. The method is of great significance for the basic theoretic researches of the oil producing fungus Mortierella alpine ATCC32222 and product development.

公开(公告)号：US20210046027A1

公开(公告)日：2021-02-18

申请号：US17085365

申请日：2020-10-30

申请人： Jiangnan University

发明人： Yongquan CHEN ,  Hongyan QU ,  Chunlei TANG ,  Guosheng WU ,  Guozhen CUI ,  Ninghan Feng ,  Xiaoying Wang ,  Kai SHAN ,  Shenglong ZHU ,  Lengyun WEI

IPC分类号： A61K31/17 ,  A61P35/00 ,  A61K31/167

摘要： The disclosure discloses a fatty acid synthase inhibitor and application thereof and belongs to the technical field of medical biology. The fatty acid synthase inhibitor of the disclosure can significantly inhibit the activity of fatty acid synthase without affecting normal expression, and adjust the ratio of fatty acids in cells. The fatty acid synthase inhibitor of the disclosure has a good tumor proliferation inhibitory effect, can arrest the growth cycle of tumor cells in the interphase, prevent tumor cell division, inhibit tumor cell proliferation, promote tumor cell apoptosis and exert a tumor treatment effect, can be used to treat tumors and metabolism related diseases, and has an important clinical application prospect.

公开(公告)号：US20190233908A1

公开(公告)日：2019-08-01

申请号：US16060417

申请日：2016-12-08

申请人： JIANGNAN UNIVERSITY

发明人： Haiqin CHEN ,  Yongquan CHEN ,  Wei CHEN ,  Tiantian MEI ,  Zhennan GU ,  Hao ZHANG

IPC分类号： C12R1/645 ,  C12N9/02 ,  C12N15/82 ,  C12N1/14

摘要： It relates to w-3 fatty acid desaturase for the synthesis of pufas from phytophthora parasitica, a plasmid containing the same, a recombinant microorganism containing the plasmid and its application. The invention also provides the use of the above ω-3 fatty acid desaturase in the biosynthesis of PUFAs, especially to catalyze C20:4Δ5,8,11,14 to C20:5Δ5,8,11,14,17 at normal temperature, with catalytic efficiency 65%. The recombinant strain reached 31.5% of the total fatty acid, and the conversion rate to AA was up to 77.6%,

公开(公告)号：US20240002461A1

公开(公告)日：2024-01-04

申请号：US18313282

申请日：2023-05-05

申请人： JIANGNAN UNIVERSITY

发明人： Shenglong ZHU ,  Yongquan CHEN

IPC分类号： C07K14/645 ,  C07K14/50 ,  A61P1/16

CPC分类号： C07K14/645 ,  C07K14/50 ,  A61P1/16 ,  C07K2319/00 ,  A61K38/00

摘要： The invention provides a fusion protein for treating metabolic diseases, and a preparation method and use thereof. The fusion protein has a general formula of R1-L-R2 or R2-L-R1, wherein R1 is FGF21 protein, an FGF21 protein analog, or a similar peptide with the biological function of FGF21 protein; R2 is GIP, mutant GIP or a similar peptide with the biological function of GIP; and L is a linker peptide. The fusion protein of the present invention is used as a therapeutic agent or a pharmaceutical composition in the treatment of diseases associated with hyperglycemia and hyperlipidemia, including diabetes, obesity, steatohepatitis or cardiovascular diseases, with a therapeutic effect significantly better than that of original FGF21 and GIP.

公开(公告)号：US20190246663A1

公开(公告)日：2019-08-15

申请号：US16390947

申请日：2019-04-22

申请人： Jiangnan University

发明人： Haiqin CHEN ,  Yongquan CHEN ,  Wei CHEN ,  Chengfeng GE ,  Xin TANG ,  Zhennan GU ,  Hao ZHANG

IPC分类号： A23K10/14 ,  C12N1/14 ,  A23K20/158 ,  A23K50/75

CPC分类号： A23K10/14 ,  A23K20/158 ,  A23K50/75 ,  C12N1/14 ,  C12N2500/05 ,  C12N2500/34 ,  C12N2500/76

摘要： The present disclosure discloses preparation of M. alpina CCFM698 thalli and application thereof in a feed additive, and belongs to the field of biological engineering and feed additives. The total fatty acid content of the M. alpina dried thalli obtained by the present disclosure is 30%-40% by weight of the dried thalli, and the EPA content is 24% or more by weight of total fatty acids. The dosage of the dried thalli in the feed in the disclosure is 0.5-1.5% of the total weight of the basal feed. The thallus feed additive is reasonable in fatty acid composition and very high in EPA content and can be used for producing high-DHA eggs which are beneficial to body health of eaters. The DHA content in each of eggs laid by laying hens fed with the feed containing the feed additive of the present disclosure reaches about 120 mg which is obviously higher than that in the prior art.

公开(公告)号：US20220339175A1

公开(公告)日：2022-10-27

申请号：US17860451

申请日：2022-07-08

申请人： Jiangnan University

发明人： Yongquan CHEN ,  Rong WANG ,  Lu XU ,  Xiaoying WANG ,  Shenglong ZHU

IPC分类号： A61K31/702 ,  A61P35/00 ,  A61P13/08 ,  A61K31/4166

摘要： Disclosed is an application of Stachyose in preparation of a drug for treating castration-resistant prostate cancer, belonging to the technical field of biological medicine. The disclosure proposes a new strategy of using Stachyose in combination with an androgen receptor antagonist to prepare a drug for treating CRPC for the first time, and conducts multi-angle and multi-level verification research. The drug composition of the Stachyose in combination with the androgen receptor in the disclosure can be used for treating castration-resistant prostate cancer, and significantly improves the effect of Enzalutamide on inhibiting castration-resistant prostate cancer. The natural compound is applied to the advanced stage of cancer, and has important clinical therapeutic significance.

公开(公告)号：US20160289690A1

公开(公告)日：2016-10-06

申请号：US15032639

申请日：2014-03-04

申请人： JIANGNAN UNIVERSITY

发明人： Yongquan CHEN ,  WEL CHEN ,  GUANGFEI HAO ,  HAIQIN CHEN ,  JIANXIN ZHAO ,  ZHENNAN GU ,  HAO ZHANG ,  DANHUI HAO ,  SHANSHAN ZHAO

IPC分类号： C12N15/80 ,  C12N9/04

CPC分类号： C12N15/80 ,  C12N9/0006 ,  C12P7/6463 ,  C12Y101/01038 ,  C12Y101/0104

摘要： It relates to a Mortierella alpina recombinant gene expression system, to its construction method and application which is constructed by transformation of M. alpina ATCC 32222 uracil auxotroph strain through A. tumefaciens mediate transformation (ATMT) and is based on the existing uracil auxotrophic strain, through genetic engineering methods to obtain a final phenotype complementary strain to achieve the malic enzyme 1 and malic enzyme 2 overexpression strains.

摘要翻译： 其涉及高山被孢霉重组基因表达系统，其构建方法和应用是通过根瘤土壤杆菌介导转化（ATMT）转化的马鞭霉ATCC 32222尿嘧啶营养缺陷型菌株构建的，并且基于现有的尿嘧啶营养缺陷型菌株， 通过基因工程方法获得最终的表型互补菌株，以达到苹果酸1和苹果酸2的过表达菌株。